Tests oral semaglutide tablets for weight loss in adults with excess weight
Compares lower doses of oral semaglutide with placebo tablets in adults with overweight or obesity.
Plain-language title generated from the registry record
Registry title: Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
Key facts
- Where
- Bydgoszcz, Lodz, Poznan, Staszow, and Warsaw, PolandSee the 8 sites
- Phase
- Phase 3
Where in Poland
- Athleticomed Sp. z o.o.Bydgoszcz, PolandTaking people
- Centrum Kardiometaboliczne Gierach-Med Marcin GierachBydgoszcz, PolandTaking people
- Santa SP. z o.oLodz, PolandTaking people
- Centrum Zdrowia Metabolicznego Paweł BogdańskiPoznan, PolandTaking people
- Velocity Nova Sp. z o.o.Staszow, PolandTaking people
- Care Access Polska Sp. Z o.o.Warsaw, PolandTaking people
- Futuremeds Sp. z o.o.Warsaw, PolandTaking people
- Nbr Polska Tomasz KlodawskiWarsaw, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07770841EU 2025-524626-18-00
- Record updated
- 9 September 2026
- Original description
The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be used for treating participants living with overweight or obesity.Read full original descriptionShow less
Efficacy and Safety of Once Daily Oral Semaglutide in Adults With Overweight or Obesity
The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be used for treating participants living with overweight or obesity.
Inclusion: Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study; Female or male (sex at birth); Age 18 years or above at the time of signing the informed consent; Body mass index (BMI) of; ≥ 27.0 kilogram per square meter (kg/m\^2) with the presence of at least one weight-related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or CV disease; OR; ≥ 30.0 kg/m\^2; History of at least one self-reported unsuccessful dietary effort to lose body weight.
Exclusion: A self-reported change in body weight greater than (>) 5% within 90 days before screening irrespective of medical records; Consistent use of glucagon like peptide-1 (GLP-1) receptor agonists, including medication with glucagon like peptide-1 receptor agonist (GLP-1 RA) activity like dual GLP-1/gastric inhibitory peptide RAs, or amylin analogues before screening. Consistent use is defined as treatment; HbA1c ≥ 6.5% (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.